Shawn Marshall Rose
Known title: See RemarksCIK: 0002073530
Associated companies
Transaction History
| NKTX | ▲ Buy | Grant | 70,000 | $0 | 1/6/2026 | View on chart |
| NKTX | ▲ Buy | Grant | 70,000 | $0 | 1/6/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Nkarta Sets 2026 Data Reveal as CAR NK Trials Progress
Nkarta announced that it is targeting a data reveal for its outpatient CAR NK trials in 2026. The company said the trials are advancing, indicating progress toward a potential regulatory milestone. This development may influence how the market views the company’s future prospects. The stock is currently trading near its support level of $2.61.
Nkarta Sets 2026 Data Reveal as CAR NK Trials Progress. Nkarta announced that it is targeting a data reveal for its outpatient CAR NK trials in 2026. The company said the trials are advancing, indicating progress toward a potential regulatory milestone. This development may influence how the market views the company’s future prospects. The stock is currently trading near its support level of $2.61.